Paralel Advisors LLC raised its stake in Cencora, Inc. (NYSE:COR - Free Report) by 10.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,330 shares of the company's stock after purchasing an additional 936 shares during the period. Paralel Advisors LLC's holdings in Cencora were worth $2,321,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Whittier Trust Co. grew its position in shares of Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after acquiring an additional 44 shares during the last quarter. Shepherd Financial Partners LLC increased its stake in Cencora by 0.9% in the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock valued at $1,223,000 after purchasing an additional 46 shares during the period. WASHINGTON TRUST Co raised its holdings in shares of Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the last quarter. JFS Wealth Advisors LLC boosted its stake in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the period. Finally, Cullen Frost Bankers Inc. grew its holdings in shares of Cencora by 1.1% during the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock worth $1,003,000 after buying an additional 47 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.
Insider Activity
In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares in the company, valued at $85,680,732.63. This represents a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,675 shares of company stock worth $8,034,778 over the last 90 days. 10.80% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several research firms have commented on COR. Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Wells Fargo & Company upped their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Bank of America lifted their price objective on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Finally, JPMorgan Chase & Co. raised their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $284.20.
Read Our Latest Stock Report on Cencora
Cencora Price Performance
COR stock traded down $0.63 during trading on Tuesday, reaching $283.66. 344,791 shares of the company were exchanged, compared to its average volume of 1,703,633. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock's 50 day moving average price is $260.88 and its 200 day moving average price is $245.57. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $296.65. The company has a market cap of $55.01 billion, a P/E ratio of 40.35, a PEG ratio of 1.31 and a beta of 0.55.
Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.
Cencora Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.78%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio (DPR) is 31.29%.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
